Sulfonamide group-containing polysiloxane compound and method for producing same
Sulfonamide group-containing polysiloxane compounds address the compatibility and phase separation issues in medical materials by enhancing hydrophilicity and transparency, leading to improved medical materials with enhanced properties.
Patent Information
- Application Number
- PCT/JP2026/016692
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-04-27
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional siloxane compounds used in medical materials face issues of phase separation and clouding due to insufficient hydrophilicity and compatibility with hydrophilic monomers, leading to heterogeneous copolymerization reactions.
Development of sulfonamide group-containing polysiloxane compounds with specific structural formulas that enhance compatibility with hydrophilic monomers, preventing phase separation and ensuring transparency through controlled copolymerization reactions.
The sulfonamide group-containing polysiloxane compounds exhibit excellent compatibility and transparency, resulting in high-quality medical materials with improved hydrophilicity, strength, and flexibility.
Smart Images

Figure JP2026016692_19112026_PF_FP_ABST
Abstract
Description
Sulfonamide group-containing polysiloxane compounds and methods for producing the same
[0001] The present invention relates to a sulfonamide group-containing polysiloxane compound and a method for producing the same.
[0002] Conventionally, monomers containing siloxanes have been known as compounds used in medical materials, including ophthalmic devices. For example, 3-[tris(trimethylsiloxy)silyl]propyl methacrylate (TRIS) is widely used as a monomer for ophthalmic devices. Polymers obtained by copolymerizing TRIS with hydrophilic monomers such as N,N-dimethylacrylamide or N-vinyl-2-pyrrolidone have the beneficial characteristic of high oxygen permeability. However, highly hydrophobic siloxane monomers do not have high compatibility with these hydrophilic monomers, and a problem arises in that phase separation occurs and clouding occurs when hydrogels for medical materials are prepared.
[0003] Patent Document 1 describes a siloxane compound having a (meth)acrylamide group. Because this compound has a carbonylamide group in its molecule, it is given hydrophilicity, improving its compatibility with hydrophilic monomers. However, if the hydrophilicity of the carbonylamide group is insufficient, many other monomers for medical materials have a (meth)acrylic group, and therefore their reactivity differs from that of this compound. This can lead to heterogeneous copolymerization reactions, potentially causing phase separation and resulting in heterogeneity in the resulting material.
[0004] Patent documents 2 and 3 describe siloxane compounds having a (meth)acrylic group and a carbonylamide group at its linking site. Because these compounds have a (meth)acrylic group, the problems of the copolymerization reaction described above are improved, and the resulting material tends to be more homogeneous. However, if the hydrophilicity of the carbonylamide group is insufficient, the resulting material may still become cloudy.
[0005] Therefore, conventional siloxane compounds cannot provide medical materials with beneficial hydrophilicity. Consequently, there remains a demand for compounds and compositions that overcome these shortcomings.
[0006] Japanese Patent Publication No. 5-17577, Japanese Patent Publication No. 2022-143180, Japanese Patent Publication No. 2022-143203
[0007] This invention has been made in view of the above circumstances, and aims to provide a sulfonamide group-containing polysiloxane compound suitable for medical materials and a method for producing the same.
[0008] To solve the above problems, the present invention provides a sulfonamide group-containing polysiloxane compound represented by the following formula (1). (In formula (1), R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are groups that are independently defined by R above, or groups represented by the following formula (2), and R 2 These are groups that are independent of each other and represented by the following formula (2), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by the following formula (2). (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group; L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms; L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms, which may contain an ether bond; the parts indicated by * are bonding sites with silicon atoms in formula (1); and the dashed lines represent bonding hands with silicon atoms.)
[0009] Such polysiloxane compounds containing sulfonamide groups exhibit excellent compatibility with hydrophilic monomers due to the presence of sulfonamide groups, and can prevent turbidity caused by phase separation during copolymerization.
[0010] Furthermore, in the present invention, it is preferable that in formula (2), M is a (meth)acryloyl group, L1 is a propylene group, and L2 is a propylene group.
[0011] Furthermore, in the present invention, it is preferable that in formula (2), M is an acrylamide group, L1 is a butylene group, and L2 is a propylene group.
[0012] Further, in the present invention, in the formula (2), it is preferable that M is a styryl group, L1 is a single bond, and L2 is a propylene group.
[0013] In the sulfonamide group-containing polysiloxane compound of the present invention, the combination of the groups as described above is preferable, and a polymer derived from such a radically polymerizable group is excellent in transparency.
[0014] Further, in the present invention, in the formula (1), R 1 are each represented by the same formula (2), and q is preferably 0.
[0015] A sulfonamide group-containing polysiloxane compound having such siloxane units is excellent as a compound used for medical materials.
[0016] Furthermore, the present invention provides a polymer comprising a repeating unit derived from polymerization of the (meth)acryloxy group of the above sulfonamide group-containing polysiloxane compound.
[0017] Such a polymer has favorable transparency.
[0018] Further, in the present invention, it is preferable that the mass proportion of the repeating unit is 10 mass% or more relative to the total mass of the polymer.
[0019] When the content is 10 mass% or more, the characteristics of the sulfonamide group-containing polysiloxane compound of the present invention are easily exhibited.
[0020] Furthermore, the present invention provides a hydrogel comprising the above polymer.
[0021] Such a hydrogel has high transparency and strength, an excellent elastic modulus and maximum elongation, and can provide a medical material having beneficial hydrophilicity, sufficient strength and flexibility.
[0022] Furthermore, the present invention provides a medical material comprising the above polymer.
[0023] Such a medical material has beneficial hydrophilicity, sufficient strength and flexibility.
[0024] Further, the present invention provides a method for producing a sulfonamide group-containing polysiloxane compound represented by the following formula (1), the method comprising: (In formula (1), R is, independently of each other, a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 is, independently of each other, the group defined for R above, or a group represented by the following formula (2), R 2 is, independently of each other, a group represented by the following formula (2), p is an integer of 0 to 100, q is an integer of 0 to 10, the bonding order of siloxane units is not limited to the above, and the units may have block units or be bonded randomly. Provided that at least one of R 1 and R 2 is a group represented by the following formula (2).) (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group, L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms, L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms which may contain an ether bond, the position marked with * is the bonding site to the silicon atom in the formula (1), and the dashed line represents a bond to the silicon atom.) The method for producing the sulfonamide group-containing polysiloxane compound is characterized by comprising the step of reacting a siloxane compound having an amino group represented by the following formula (3) with a sulfonic acid halide having a radical polymerizable group represented by the following formula (5) in the presence of an organic base to obtain the sulfonamide group-containing polysiloxane compound represented by the formula (1). (In formula (3), R is, independently of each other, a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 is, independently of each other, the group defined for R above, or a group represented by the following formula (4), R 2 is, independently of each other, a group represented by the following formula (4), p is an integer of 0 to 100, q is an integer of 0 to 10, the bonding order of siloxane units is not limited to the above, and the units may have block units or be bonded randomly. Provided that at least one of R 1 and R 2 is a group represented by the following formula (4).) (In formula (4), L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms that may contain an ether bond, the part indicated by * is the bond site with the silicon atom in formula (3), and the dashed line represents the bond with the silicon atom.) (In formula (5), M and L1 are as described above, and X represents a chlorine atom, a bromine atom, or an iodine atom.)
[0025] With this manufacturing method, undesirable side reactions can be suppressed by inhibiting hydrogen abstraction from the sulfonamide group, and the target sulfonamide group-containing polysiloxane compound can be obtained in high purity.
[0026] Furthermore, in the present invention, it is preferable to use an aliphatic amine or heterocyclic amine with a pKa of 12 or less as the organic base.
[0027] Furthermore, in the present invention, it is preferable to use a trialkylamine or a pyridine derivative as the organic base.
[0028] With a production method using such an organic base, hydrogen abstraction from the sulfonamide group can be further suppressed, undesirable side reactions can be further reduced, and the sulfonamide group-containing polysiloxane compound of the present invention can be obtained in even higher purity.
[0029] As described above, the sulfonamide group-containing polysiloxane compound of the present invention exhibits excellent compatibility with hydrophilic monomers due to the presence of sulfonamide groups, and can prevent turbidity caused by phase separation during copolymerization. Furthermore, the (co)polymer containing repeating units derived from the polymerization of the polymerizable groups of the sulfonamide group-containing polysiloxane compound of the present invention has desirable transparency. The sulfonamide group-containing polysiloxane compound of the present invention is useful as a monomer for medical materials. The method for producing the sulfonamide group-containing polysiloxane compound of the present invention makes it possible to obtain such useful sulfonamide group-containing polysiloxane compounds in high purity.
[0030] As mentioned above, there was a need for the development of sulfonamide group-containing polysiloxane compounds suitable for medical materials and methods for producing them.
[0031] The inventors of the present invention have diligently studied to solve the above problems and have found that a compound having a siloxane unit and a radical polymerizable group, and having a sulfonamide group at its linking group site, exhibits excellent compatibility with other monomers, including hydrophilic monomers, and good reactivity. Furthermore, they have found that the sulfonamide group-containing polysiloxane compound obtained by reacting a siloxane compound having an amino group with a sulfonic acid halide having a radical polymerizable group in the presence of an organic base is of high purity and is preferable as a raw material for (meth)acrylic resins, thus completing the present invention.
[0032] In other words, the present invention is a sulfonamide group-containing polysiloxane compound represented by the following formula (1). (In formula (1), R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are groups that are independently defined by R above, or groups represented by the following formula (2), and R 2 These are groups that are independent of each other and represented by the following formula (2), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by formula (2). (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group; L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms; L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms, which may contain an ether bond; the parts indicated by * are bonding sites with silicon atoms in formula (1); and the dashed lines represent bonding hands with silicon atoms.)
[0033] Furthermore, the present invention provides a method for producing the sulfonamide group-containing polysiloxane compound, a polymer containing repeating units derived from the sulfonamide group-containing polysiloxane compound, and a hydrogel and medical material, particularly an ophthalmic device, containing the polymer.
[0034] The sulfonamide group-containing polysiloxane compounds of the present invention will be described in detail below, but the present invention is not limited to these.
[0035] [Sulfonamide Group-Containing Polysiloxane Compound] The sulfonamide group-containing polysiloxane compound of the present invention (which may be simply referred to as a polysiloxane compound in this specification) is a polysiloxane compound represented by the following formula (1), and is characterized by having a siloxane unit, a sulfonamide group, and a radical polymerizable group. Because the polysiloxane compound has a sulfonamide group, it has excellent compatibility with other monomers, and the polymer derived from the radical polymerizable group has excellent transparency. (In formula (1), R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are groups that are independently defined by R above, or groups represented by the following formula (2), and R 2 These are groups that are independent of each other and represented by the following formula (2), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by formula (2). (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group; L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms; L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms, which may contain an ether bond; the parts indicated by * are bonding sites with silicon atoms in formula (1); and the dashed lines represent bonding hands with silicon atoms.)
[0036] In formula (1) above, R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms. Examples of monovalent hydrocarbon groups include alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl groups; cycloalkyl groups such as cyclopentyl and cyclohexyl groups; and aryl groups such as phenyl and tolyl groups. R is preferably an alkyl group or phenyl group having 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably a methyl group.
[0037] In the above formula (1), R 1 These are, independently of each other, a group defined by R above, or a group represented by formula (2) above, and R 2 These are groups that are independently represented by formula (2). However, the siloxane compound represented by formula (1) is characterized by having one or more groups represented by formula (2) in one molecule, preferably 2 to 10 groups, more preferably 2 to 8 groups, and more preferably 2 to 5 groups, represented by formula (2) in one molecule.
[0038] In formula (2) above, M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group. Preferably, it is a (meth)acryloyl group.
[0039] In formula (2) above, L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms.
[0040] Examples of single bonds or divalent hydrocarbon groups having 1 to 5 carbon atoms include single bonds, methylene groups, ethylene groups, 1,3-propylene groups, 1-methylpropylene groups, 1,1-dimethylethylene groups, 1,1-dimethylpropylene groups, 2-methylpropylene groups, 1,2-dimethylpropylene groups, 1,4-butylene groups, 2-methyl-1,4-butylene groups, 3-methyl-1,4-butylene groups, and 1,5-pentylene groups. Preferably, the single bonds, 1,3-propylene groups, 1,4-butylene groups, 1,5-pentylene groups, and 1,1-dimethylethylene groups are used.
[0041] In formula (2) above, L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms that may contain an ether bond.
[0042] Examples of L2 include, for example, an ethylene group, a 1,3-propylene group, a 1-methylpropylene group, a 1,1-dimethylpropylene group, a 2-methylpropylene group, a 1,2-dimethylpropylene group, a 1,1,2-trimethylpropylene group, a 1,4-butylene group, a 2-methyl-1,4-butylene group, a 2,2-dimethyl-1,4-butylene group, a 3-methyl-1,4-butylene group, a 2,2-dimethyl-1,4-butylene group, a 2,3-dimethyl-1,4-butylene group, a 2,2,3-trimethyl-1,4-butylene group, a 1,5-pentylene group, a 1,6-hexanylene group, a 1,7-heptanylene group, a 1,8-octanylene group, a 1,9-nonanylene group, and a 1,10-decanylene group. Examples of groups containing an ether linkage include polyoxyalkylene groups such as polyoxyethylene groups, polyoxypropylene groups, and polyoxyethylene-polyoxypropylene groups. Preferably, it is a 1,3-propylene group.
[0043] In formula (1) above, preferred combinations are: M is a (meth)acryloyl group, L1 is a propylene group, and L2 is a propylene group; M is an acrylamide group, L1 is a butylene group, and L2 is a propylene group; or M is a styryl group, L1 is a single bond, and L2 is a propylene group.
[0044] In formula (1) above, p is an integer between 0 and 100, preferably between 0 and 50, and more preferably between 10 and 40.
[0045] In formula (1) above, q is an integer from 0 to 10, preferably an integer from 0 to 8, and more preferably 0 or an integer from 2 to 5. When q is 0, R 1 These are all groups represented by formula (2) above.
[0046] In formula (1) above, the bonding order of the siloxane units is not restricted; they may form block units or be bonded randomly. When q is 0, the siloxane compound has one of the groups represented by formula (2) at each end.
[0047] [Method for Producing Polysiloxane Compounds] The method for producing the polysiloxane compound represented by formula (1) above will be described below. The method for producing the polysiloxane compound of the present invention involves a siloxane compound having an amino group, represented by the following formula (3), (In formula (3), R is a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are groups that are independently defined by R above, or groups represented by the following formula (4), and R 2 These are groups that are independent of each other and represented by the following formula (4), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by formula (4). (In formula (4), L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms that may contain an ether bond, the part indicated by * is the bond site with the silicon atom in formula (3), and the dashed line represents the bond with the silicon atom.) A sulfonic acid halide having a radical polymerizable group represented by the following formula (5) (In formula (5), M and L1 are as described above, and X represents a chlorine atom, a bromine atom, or an iodine atom.) This is a method for producing a polysiloxane compound, comprising the step of reacting in the presence of an organic base to obtain a compound represented by the above formula (1).
[0048] The method for producing the polysiloxane compound of the present invention preferably uses a specific organic base as a raw material. In the method for producing the polysiloxane compound of the present invention, it is necessary to use a base to remove the by-product hydrogen halide, but the organic base can suppress hydrogen abstraction from the sulfonamide group, thereby suppressing undesirable side reactions. As a result, the polysiloxane compound of the present invention can be obtained in high purity.
[0049] The above reaction may be carried out according to conventionally known methods. In the present invention, a siloxane compound having an amino group, represented by (3), may be reacted with the addition of, for example, 1 molar equivalent or more of a sulfonic acid halide having a radical polymerizable group, represented by (5), in the presence of an organic base. The reaction temperature is not particularly limited, but a temperature that does not exceed the boiling point of the solvent used is preferred. For example, it is preferable to carry out the reaction at a temperature of about 0°C to about 80°C. The above reaction may be carried out in the presence of a solvent or stabilizer. The solvent and stabilizer may be any conventionally known one and are not particularly limited.
[0050] In the above reaction, it is preferable to add the sulfonic acid halide having a radical polymerizable group in an amount of 1 molar equivalent or more relative to the siloxane compound having an amino group. More preferably, it is 1.0 to 3.0 molar equivalents, even more preferably 1.1 to 2.0 molar equivalents, and particularly preferably 1.2 to 1.5 molar equivalents. Adding 1 molar equivalent or more of the sulfonic acid halide having a radical polymerizable group relative to the siloxane compound having an amino group can suppress the residue of the siloxane compound having an amino group and prevent side reactions. Furthermore, there is no upper limit, but an amount of 3.0 molar equivalents or less is preferable from the viewpoint of yield and economic efficiency.
[0051] In the above reaction, it is preferable to add the organic base in an amount of 1 molar equivalent or more relative to the sulfonic acid halide having a radical polymerizable group. More preferably, it is 1.0 to 3.0 molar equivalents, even more preferably 1.1 to 2.0 molar equivalents, and particularly preferably 1.2 to 1.5 molar equivalents. Adding an organic base in an amount of 1 molar equivalent or more relative to the sulfonic acid halide having a radical polymerizable group can suppress the residue of siloxane compounds having amino groups and side reactions. Furthermore, there is no upper limit, but an amount of 3.0 molar equivalents or less is preferable from the viewpoint of yield and economic efficiency.
[0052] (Organic Bases) Organic bases are bases made of organic compounds, and examples include aliphatic amines and heterocyclic amines. In the present invention, it is preferable that the strong organic base has low nucleophilicity and high basicity. Furthermore, in order to suppress hydrogen abstraction on the sulfonamide group, it is preferable that the pKa (acid dissociation constant) is 12 or less. That is, it is preferable to use an aliphatic amine or heterocyclic amine with a pKa of 12 or less as the organic base. In addition, it is also preferable to use a trialkylamine or pyridine derivative as the organic base. Examples of such organic bases are not limited to, but include, for example, trimethylamine, triethylamine, tri-n-propylamine, triisopropylamine, tri-n-butylamine, triisobutylamine, tri-t-butylamine, trihexylamine, tri-n-octylamine, methyldiethylamine, N,N-dimethylcyclohexylamine, N,N-dimethylbenzylamine, triphenylamine, tribenzylamine, triphenethylamine, N,N-dimethylaniline, N,N,N',N'-tetraethylmethanediamine, N,N,N',N'-tetramethylethylenediamine, N,N,N',N'-tetramethyl-1,4-butanediamine, N,N,N',N'-tetramethyl-1,3-butanediamine, 1-methylpyrrole, and 1-ethylpyrrole Examples include 1-methylpyrrolidine, 1-ethylpyrrolidine, oxazole, thiazole, 1-methylimidazole, 1-ethylimidazole, 1-butylimidazole, 1-methylpyrazole, 1-methylpiperidine, 1-ethylpiperidine, N,N'-dimethylpiperazine, pyridine, N,N-dimethyl-4-aminopyridine, N,N-diethyl-4-aminopyridine, 2-methoxypyridine, 4-methoxypyridine, 2-methylpyridine, 4-methylpyridine, 2,6-dimethylpyridine, 2,4,6-trimethylpyridine, pyridazine, pyrimidine, pyrazine, quinoline, isoquinoline, quinuclidine, quinazoline, 9-methylcarbazole, acridine, phenanthridine, etc., with triethylamine, pyridine, and N,N-dimethyl-4-aminopyridine being particularly preferred. The organic bases may be used individually or in combination of two or more.
[0053] pKa is the acid dissociation constant, where pKa = -logKa, Ka = [H 3 O + ] [B - ] / [BH] (BH: organic acid, B - : Defined as the conjugate base of an organic acid. Note that pKa means the first dissociation constant pKa 1 when one molecule of the curing agent contains two or more acidic groups. The acid dissociation constant (pKa) also varies depending on the type of solvent surrounding the active hydrogen compound. In this specification, pKa in water is used as the indicator. pKa can be calculated from the concentration of the substance and the hydrogen ion concentration by measuring the hydrogen ion concentration in water using a pH meter, for example. If the pKa value is publicly known from literature, etc. (e.g., CRC Handbook of Chemistry and Physics 99th edition, Evans pKa Table (evans.rc.fas.harvard.edu / pdf / evans_pKa_table.pdf), pKa Data Compiled by R. Williams https: / / organicchemistrydata.org / hansreich / resources / pka / pka_data / pka-compilation-williams.pdf), that value may also be adopted. Furthermore, methods known to those skilled in the art can be used to determine the pKa. For example, neutralization titration, UV titration, potentiometric titration, etc., can be used, and these methods have been established over a long period of time. For example, see RF Cookson: Determination of acidity constants; Chemical Reviews, 74, 5-28 (1974).
[0054] (Solvents) Solvents that can be used in the reaction include, for example, glycol ether solvents such as methyl cellosolve, ethyl cellosolve, isopropyl cellosolve, butyl cellosolve, propylene glycol monomethyl ether, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether, polyethylene glycol monomethyl ether, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether, and polyethylene glycol dimethyl ether; ester solvents such as ethyl acetate, butyl acetate, amyl acetate, ethyl lactate, and methyl benzoate; aliphatic hydrocarbon solvents such as linear hexane, linear heptane, and linear octane; and alicyclic hydrocarbon solvents such as cyclohexane and ethylcyclohexane. Examples of suitable solvents include ketone solvents such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; and petroleum-based solvents; and alcohol-based solvents such as methyl alcohol, ethyl alcohol, linear propyl alcohol, isopropyl alcohol, linear butyl alcohol, isobutyl alcohol, tert-butyl alcohol, ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, and polyethylene glycol. Aliphatic hydrocarbon solvents such as linear hexane, linear heptane, and linear octane; alicyclic hydrocarbon solvents such as cyclohexane and ethylcyclohexane; aromatic hydrocarbon solvents such as benzene, toluene, and xylene; and petroleum-based solvents. The solvents may be used individually or in combination of two or more.
[0055] (Stabilizers) Examples of stabilizers include phenolic antioxidants, phosphorus-based antioxidants, amine-based antioxidants, and sulfur-based antioxidants. Examples of phenolic antioxidants are not particularly limited, but include compounds selected from the group consisting of p-methoxyphenol, di-tert-butyl-p-cresol, pyrogallol, tert-butylcatechol, 4,4-thiobis(3-methyl-6-tert-butylphenol), 2,2'-methylenebis(4-methyl-6-t-butylphenol), phenolic resins, and cresol resins. Examples of phosphorus-based antioxidants are not limited to these, but include tris[2-[[2,4,8,10-tetrakis(1,1-dimethylethyl)dibenzo[d,f][1,3,2]dioxaphosfepin-6-yl]oxy]ethyl]amine, tris[2-[(4,6,9,11-tetra-tert-butyldibenzo[d,f][1,3,2]dioxaphosfepin-2-yl)oxy]ethyl]amine, and ethylbis(2,4-ditert-butyl-6-methylphenyl) phosphate. Examples of amine-based antioxidants include, but are not limited to, tri or tetraC1-3 alkylpiperidine or its derivatives, bis(2,2,6,6-tetramethyl-4-piperidyl)oxalate, 1,2-bis(2,2,6,6-tetramethyl-4-piperidyloxy)ethane, phenylnaphthylamine, N,N'-diphenyl-1,4-phenylenediamine, N-phenyl-N'-cyclohexyl-1,4-phenylenediamine, and the like. Examples of sulfur-based antioxidants include, but are not limited to, dilaurylthiodipropionate and distearylthiodipropionate. The stabilizers may be used individually or in combination of two or more.
[0056] In the above reaction, the reaction endpoint can be confirmed according to conventionally known methods. For example, it can be confirmed by the disappearance of the peak of the starting compound using thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), or nuclear magnetic resonance (NMR). After the reaction is complete, the product can be purified according to conventionally known methods. For example, the product can be isolated by washing the organic layer with water and then removing the solvent. Alternatively, vacuum distillation or activated carbon treatment may be used.
[0057] As an example of a method for producing the polysiloxane compound of the present invention, 1 molar equivalent (calculated in terms of amino group content) of the siloxane compound having an amino group represented by formula (3) above, 1.5 molar equivalents of an organic base, and 300% by mass of toluene relative to the siloxane compound having an amino group are added and stirred at 5°C under a nitrogen atmosphere. 1.3 molar equivalents of the sulfonic acid halide having a radical polymerizable group represented by formula (5) above are added dropwise to this solution and the reaction is allowed to proceed. The reaction is completed after about 2 hours of reaction. The progress of the reaction can be confirmed by monitoring the siloxane compound having an amino group or the resulting compound using GC or NMR measurement. After the reaction is complete, the organic layer is washed with water, and the solvent and unreacted raw materials present in the organic layer are removed by reduced pressure distillation to obtain the polysiloxane compound represented by formula (1) above.
[0058] [Polymers] The polysiloxane compounds of the present invention can give polymers containing repeating units derived from the (addition) polymerization of the (meth)acryloxy group of the polysiloxane compound. The polysiloxane compounds of the present invention have good compatibility with other compounds having polymerizable groups such as (meth)acryloxy groups (hereinafter referred to as polymerizable monomers or hydrophilic monomers). Therefore, a colorless and transparent copolymer can be obtained by copolymerization with polymerizable monomers. Polymerization can also be carried out alone.
[0059] In the production of a copolymer containing repeating units derived from the polymerization of the polysiloxane compound of the present invention with other polymerizable (hydrophilic) monomers, the blending ratio of the polysiloxane compound of the present invention is preferably such that the mass ratio of the repeating units derived from the polysiloxane compound of the present invention is 10% by mass or more with respect to the total mass of the polymer. More specifically, the amount of repeating units derived from the (addition) polymerization of the (meth)acryloxy group of the polysiloxane compound of the present invention is preferably 10 to 80 parts by mass, more preferably 10 to 60 parts by mass, per 100 parts by mass of the total of the polysiloxane compound of the present invention and the polymerizable (hydrophilic) monomer. If the mass ratio of the repeating units is 10% by mass or more, the properties of the polysiloxane compound of the present invention are easily expressed.
[0060] Examples of polymerizable monomers include acrylic monomers such as (meth)acrylic acid, methyl (meth)acrylate, ethyl (meth)acrylate, (poly)ethylene glycol dimethacrylate, polyalkylene glycol mono(meth)acrylate, polyalkylene glycol monoalkyl ether (meth)acrylate, trifluoroethyl (meth)acrylate, 2-hydroxyethyl (meth)acrylate, and 2,3-dihydroxypropyl (meth)acrylate; acrylic acid derivatives such as N,N-dimethylacrylamide, N,N-diethylacrylamide, N-acryloylmorpholine, and N-methyl (meth)acrylamide; other unsaturated aliphatic or aromatic compounds such as N-vinylpyrrolidone, for example, crotonic acid, cinnamic acid, and vinylbenzoic acid; and siloxane monomers having polymerizable groups such as (meth)acrylic groups. These may be used individually or in combination of two or more.
[0061] Copolymerization of the polysiloxane compound of the present invention with the above-mentioned other polymerizable monomers may be carried out by conventionally known methods. For example, it can be carried out using known polymerization initiators such as thermal polymerization initiators or photopolymerization initiators. Examples of such polymerization initiators include 2-hydroxy-2-methyl-1-phenyl-propan-1-one, azobisisobutyronitrile, azobisdimethylvaleronitrile, benzoyl peroxide, tert-butyl hydroperoxide, cumene hydroperoxide, and 2,2'-azobis(2-methylpropionamidine) dihydrochloride. These polymerization initiators can be used individually or in combination of two or more. The amount of polymerization initiator added is preferably 0.001 to 2 parts by mass, and more preferably 0.01 to 1 part by mass, per 100 parts by mass of the total polymerization components.
[0062] Polymers containing repeating units derived from the polymerization of radical polymerizable groups of the polysiloxane compound of the present invention exhibit excellent hydrophilicity. Furthermore, hydrogels obtained from these polymers have high transparency and strength. Medical materials can also be obtained from these polymers. Therefore, the polysiloxane compounds of the present invention are suitable for manufacturing medical materials, such as ophthalmic devices, contact lenses, intraocular lenses, and artificial corneas. The method for manufacturing medical materials using these polymers is not particularly limited, and conventionally known methods for manufacturing medical materials may be followed. For example, when forming lenses such as contact lenses and intraocular lenses, cutting methods or molding methods can be used.
[0063] The present invention will be described in more detail below with reference to examples and comparative examples, but the present invention is not limited to the following examples.
[0064] The analytical methods used in the following examples and comparative examples are as follows: 1 ¹H-NMR analysis i. Equipment and parameters Equipment: JEOL ECS400 Pulse acquisition time: 2.1 seconds Pulse relaxation time: 5 seconds Number of integrations: 256 times ii. Sample preparation The sample was diluted to 10% by mass with deuterated chloroform and placed in a 5 mm inner diameter NMR tube.
[0065] The compounds used in the following examples and comparative examples are as follows: SiGMA: Compound represented by formula (6) or (6)' di-AMAS30: Compound represented by formula (7)
[0066] [Synthesis Example 1] In a 500 mL three-necked round-bottom flask equipped with a Liebig flask and thermometer, 50.0 g of a siloxane compound having an amino group represented by formula (10) below (MW = approximately 2470), 6.1 g of triethylamine (pKa = 10.7, molar ratio to amino group = 1.5), and 150.0 g of toluene were added under a nitrogen atmosphere. While maintaining the internal temperature at 5°C, 11.9 g of 3-methacryloyloxypropanesulfonyl chloride (molar ratio to amino group = 1.3) was added dropwise. After addition, the mixture was aged at room temperature for 2 hours. After the reaction, the mixture was washed once with water, twice with 5% aqueous caustic soda solution, and three times with water. The solvent and unreacted starting materials were removed by distillation under reduced pressure at an internal temperature of 80°C to obtain the compound represented by formula (11) below. Yield: 50.3 g. The pKa values for this synthesis example were taken from the CRC Handbook of Chemistry and Physics 99th edition.
[0067] [Synthesis Example 2] The compound represented by the following formula (12) was obtained by the same method as in Synthesis Example 1, except that 3-methacryloyloxypropanesulfonyl chloride was replaced with 50.0 g of 4-styrenesulfonyl chloride. Yield: 52.2 g.
[0068] [Synthesis Example 3] The compound represented by formula (14) below was obtained in the same manner as in Synthesis Example 1, except that 3-methacryloyloxypropanesulfonyl chloride was replaced with 50.0 g of a sulfonic acid halide having a radical polymerizable group represented by formula (13) below. Yield: 46.2 g.
[0069] [Synthesis Example 4] The compound represented by formula (16) below was obtained in the same manner as in Synthesis Example 1, except that the siloxane compound having an amino group represented by (10) in Synthesis Example 1 was replaced with 50.0 g of the siloxane compound having an amino group represented by formula (15) below. Yield: 54.1 g.
[0070] [Synthesis Example 5] The compound represented by formula (18) below was obtained in the same manner as in Synthesis Example 1, except that the siloxane compound having an amino group represented by (10) below was replaced with 50.0 g of the siloxane compound having an amino group represented by formula (17) below. Yield: 55.5 g.
[0071] [Synthesis Example 6] The compound represented by formula (11) above was obtained in the same manner as in Synthesis Example 1, except that triethylamine was replaced with pyridine (pKa = 5.2). Yield: 50.8 g. The pKa values for this synthesis example were taken from the CRC Handbook of Chemistry and Physics 99th edition.
[0072] [Comparative Synthesis Example 1] The compound was obtained in the same manner as in Synthesis Example 1, except that triethylamine was replaced with 8.5 g of 1,5,7-triazabicyclo[4.4.0]deca-5-ene (TBD) (pKa = 14.5). Yield: 46.5 g. The pKa values for this comparative synthesis example were taken from Croat. Chem. Acta 87 (4) (2014) 385-395.
[0073] [Comparative Synthesis Example 2] The compound was obtained in the same manner as in Synthesis Example 1, except that triethylamine was replaced with 12.1 g of a 20% aqueous solution of caustic soda. Yield: 39.8 g.
[0074] [Examples 1-5 and Comparative Examples 1-3] [Hydrogel Preparation Example] Each compound obtained in Synthesis Examples 1-5, each compound obtained in Comparative Synthesis Examples 1-2, di-AMAS 30 represented by the above formula, 2-hydroxyethyl methacrylate (HEMA), N,N-dimethylacrylamide (DMA), 2-methacryloyloxyethyl phosphorylcholine (MPC), and Irgacure 1173 (IRG1173) were mixed in the composition and mixing ratio shown in Table 1 and stirred until a homogeneous solution was obtained. After stirring, N 2 After bubbling for 5 minutes and thoroughly degassing, the material was sealed in a polypropylene mold. It was cured by UV irradiation using a high-pressure mercury lamp. After curing, the material was washed by immersing it in isopropanol, a 50% isopropanol aqueous solution, and deionized water for several seconds each, to obtain a hydrogel film. The physical properties of the obtained film were measured according to the method described below. The results are shown in Table 1.
[0075] [Equilibrium Moisture Content] The film was immersed in deionized water at 25°C for 48 hours, then the surface moisture was wiped off, and the mass of the hydrated film was measured. Next, the hydrated film was dried in a 50°C oven for 48 hours and then in a 25°C oven for 24 hours, and the mass of the dried film was measured. The equilibrium moisture content was calculated using the following formula: Equilibrium moisture content (%) = 100 × (Mass of hydrated film - Mass of dried film) / Mass of hydrated film
[0076] [Transparency] The film was immersed in deionized water at 25°C for 48 hours, then the surface moisture was wiped off to prepare a hydrated film. Its appearance was observed visually and evaluated according to the following indicators: A: Uniform and transparent B: Non-uniform or cloudy
[0077] [Elastic Modulus (Young's Modulus) and Elongation] After immersing the film in deionized water at 25°C for 48 hours, the surface moisture was wiped off to prepare a hydrated film. The Young's modulus of the hydrated film was measured using Instron 5943. The film, cut into 0.8 cm × 4.0 cm pieces, was measured using a 50 N load cell and a head speed of 1 cm / min. The slope of the initial (straight) portion of the stress-strain curve, with stress on the vertical axis and strain on the horizontal axis, was calculated and defined as the Young's modulus (MPa). The elongation at the time of film breakage was defined as the maximum elongation (%).
[0078]
[0079] As shown in Synthesis Examples 1-6 and Comparative Synthesis Examples 1-2, the organic base suppresses hydrogen abstraction from the sulfonamide group, thereby suppressing side reactions during reactions with sulfonic acid halides having radical polymerizable groups, and enabling the production of polysiloxane compounds with high purity.
[0080] As shown in the table, the hydrogel using di-AMAS30 as the comparative compound has poor transparency (Comparative Example 1). Furthermore, the hydrogels using Comparative Synthesis Examples 1 and 2 as comparative compounds have high elastic modulus and low maximum elongation (Comparative Examples 2 and 3). This is because the desired structure could not be obtained due to side reactions during the reaction with the sulfonic acid halide having a radical polymerizable group. On the other hand, as shown in the table, the hydrogel using the polysiloxane compound of the present invention has excellent transparency, excellent elastic modulus and maximum elongation. In other words, the hydrogel using the polysiloxane compound of the present invention provides a medical material with beneficial hydrophilicity, sufficient strength and flexibility.
[0081] This specification includes the following embodiments: [1]: A sulfonamide group-containing polysiloxane compound represented by the following formula (1). (In formula (1), R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are groups that are independently defined by R above, or groups represented by the following formula (2), and R 2These are groups that are independent of each other and represented by the following formula (2), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by the following formula (2). (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group; L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms; L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms, which may contain an ether bond; the parts indicated by * are bonding sites with silicon atoms in formula (1); and the dashed lines represent bonding hands with silicon atoms.) [2]: The sulfonamide group-containing polysiloxane compound of the above [1], characterized in that in formula (2), M is a (meth)acryloyl group, L1 is a propylene group, and L2 is a propylene group. [3]: The sulfonamide group-containing polysiloxane compound of the above [1], characterized in that in formula (2), M is an acrylamide group, L1 is a butylene group, and L2 is a propylene group. [4]: The sulfonamide group-containing polysiloxane compound of [1], characterized in that in formula (2), M is a styryl group, L1 is a single bond, and L2 is a propylene group. [5]: In formula (1), R 1 A sulfonamide group-containing polysiloxane compound according to any one of [1] to [4] above, characterized in that it is represented by the same formula (2) and q is 0. [6]: A polymer characterized in that it contains repeating units derived from the polymerization of (meth)acryloxy groups of the sulfonamide group-containing polysiloxane compound according to any one of [1] to [5] above. [7]: The polymer of [6] above, characterized in that the mass percentage of the repeating units is 10% by mass or more with respect to the total mass of the polymer. [8]: A hydrogel characterized in that it contains the polymer of [6] or [7] above. [9]: A medical material characterized in that it contains the polymer of [6] or [7] above.
[10] : A method for producing a sulfonamide group-containing polysiloxane compound represented by the following formula (1), (In formula (1), R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are groups that are independently defined by R above, or groups represented by the following formula (2), and R 2 These are groups that are independent of each other and represented by the following formula (2), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by the following formula (2). (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group; L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms; L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms which may contain an ether bond; the part indicated by * is the bond site with the silicon atom in formula (1); and the dashed line represents the bond with the silicon atom.) A method for producing the sulfonamide group-containing polysiloxane compound, characterized by comprising the step of reacting a siloxane compound having an amino group represented by the following formula (3) with a sulfonic acid halide having a radical polymerizable group represented by the following formula (5) in the presence of an organic base to obtain the sulfonamide group-containing polysiloxane compound represented by formula (1). (In formula (3), R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are, independently of each other, a group defined by R, or a group represented by the following formula (4), where R 2 These are groups that are independent of each other and represented by the following formula (4), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by the following formula (4). (In formula (4), L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms that may contain an ether bond, the part indicated by * is the bond site with the silicon atom in formula (3), and the dashed line represents the bond with the silicon atom.) (In formula (5), M and L1 are as described above, and X represents a chlorine atom, a bromine atom, or an iodine atom.)
[11] : The method for producing
[10] , characterized in that the organic base is an aliphatic amine or a heterocyclic amine having a pKa of 12 or less.
[12] : The method for producing
[10] or
[11] , characterized in that the organic base is a trialkylamine or a pyridine derivative.
[0082] [Industrial Applicability] The polysiloxane compounds of the present invention provide hydrogels with excellent hydrophilicity and strength. The polysiloxane compounds of the present invention are useful as monomers for medical materials, such as ophthalmic devices, contact lenses, intraocular lenses, artificial corneas, and spectacle lenses.
[0083] It should be noted that the present invention is not limited to the embodiments described above. The embodiments described above are illustrative, and any configuration that is substantially identical to the technical idea described in the claims of the present invention and achieves similar effects is included within the technical scope of the present invention.
Claims
1. A polysiloxane compound containing a sulfonamide group, represented by the following formula (1). (In formula (1), R is independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 These are groups that are independently defined by R above, or groups represented by the following formula (2), and R 2 These are groups that are independent of each other and represented by the following formula (2), where p is an integer from 0 to 100, and q is an integer from 0 to 10. The bonding order of the siloxane units is not limited to the above, and they may have block units or be bonded randomly. However, R 1 and R 2 At least one of them is a base represented by the following formula (2). (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group; L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms; L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms, which may contain an ether bond; the parts indicated by * are bonding sites with silicon atoms in formula (1); and the dashed lines represent bonding sites with silicon atoms.) 2. The sulfonamide group-containing polysiloxane compound according to claim 1, characterized in that, in formula (2), M is a (meth)acryloyl group, L1 is a propylene group, and L2 is a propylene group.
3. The sulfonamide group-containing polysiloxane compound according to claim 1, characterized in that, in formula (2), M is an acrylamide group, L1 is a butylene group, and L2 is a propylene group.
4. The sulfonamide group-containing polysiloxane compound according to claim 1, characterized in that, in formula (2), M is a styryl group, L1 is a single bond, and L2 is a propylene group.
5. In the above formula (1), R 1 The sulfonamide group-containing polysiloxane compound according to claim 1, characterized in that it is represented by the same formula (2) and q is 0.
6. A polymer characterized by comprising repeating units derived from the polymerization of (meth)acryloxy groups of a sulfonamide group-containing polysiloxane compound according to any one of claims 1 to 5.
7. The polymer according to claim 6, characterized in that the mass percentage of the repeating units is 10% by mass or more with respect to the total mass of the polymer.
8. A hydrogel characterized by containing the polymer described in claim 6.
9. A medical material characterized by containing the polymer described in claim 6.
10. A method for producing a sulfonamide group-containing polysiloxane compound represented by the following formula (1), the method comprising: (In formula (1), R is each independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 is each independently a group defined for R above, or a group represented by the following formula (2), R 2 is each independently a group represented by the following formula (2), p is an integer of 0 to 100, q is an integer of 0 to 10, the bonding order of siloxane units is not limited to the above, and the units may have block units or be bonded randomly. Provided that at least one of R 1 and R 2 is a group represented by the following formula (2.) (In formula (2), M is a (meth)acryloyl group, a (meth)acrylamide group, or a styryl group, L1 is a single bond or a divalent hydrocarbon group having 1 to 5 carbon atoms, L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms which may contain an ether bond, the position marked with * is the bonding site to the silicon atom in the aforementioned formula (1), and the dashed line represents the bond to the silicon atom.) A method for producing the sulfonamide group-containing polysiloxane compound, comprising the step of reacting a siloxane compound having an amino group represented by the following formula (3) with a sulfonic acid halide having a radical polymerizable group represented by the following formula (5) in the presence of an organic base, to obtain the sulfonamide group-containing polysiloxane compound represented by the aforementioned formula (1). (In formula (3), R is each independently a monovalent hydrocarbon group having 1 to 10 carbon atoms, R 1 is each independently a group defined for the aforementioned R, or a group represented by the following formula (4), R 2 is each independently a group represented by the following formula (4), p is an integer of 0 to 100, q is an integer of 0 to 10, the bonding order of siloxane units is not limited to the above, and the units may have block units or be bonded randomly. Provided that at least one of R 1 and R 2 is a group represented by the following formula (4.) (In formula (4), L2 is a divalent hydrocarbon group having 2 to 10 carbon atoms that may contain an ether bond, the part indicated by * is the bond site with the silicon atom in formula (3), and the dashed line represents the bond with the silicon atom.) (In formula (5), M and L1 are as described above, and X represents a chlorine atom, a bromine atom, or an iodine atom.) 11. The manufacturing method according to claim 10, characterized in that the organic base is an aliphatic amine or a heterocyclic amine having a pKa of 12 or less.
12. The manufacturing method according to claim 10, characterized in that a trialkylamine or pyridine derivative is used as the organic base.
